JP Morgan Private Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,553	Closed	-$265K	–	1799
2020 Q4	$265K	Sell	1,553 -7	-0.4%	-$1.04K	﹤0.01%	1546
2020 Q3	$219K	Buy	1,560 +100	+7%	+$15.2K	﹤0.01%	1492
2020 Q2	$234K	Buy	+1,460	New	+$199K	﹤0.01%	1405
2019 Q3	–	Sell	-1,763	Closed	-$268K	–	1478
2019 Q2	$268K	Buy	+1,763	New	+$214K	﹤0.01%	1191

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Private Wealth Advisors's SRPT Position: Q1 2021 in Review

JP Morgan Private Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,553 shares — an estimated $265K sold.

JP Morgan Private Wealth Advisors first reported a position in SRPT in Q2 2019 and held it in 4 quarters. The position peaked at $268K in Q2 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

JP Morgan Private Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 1,553 Sarepta Therapeutics shares in Q1 2021, an estimated $265K.
JP Morgan Private Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 4 quarters.
JP Morgan Private Wealth Advisors's Sarepta Therapeutics position peaked at $268K in Q2 2019.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q1 2021, filed 14 May 2021.